BusinessAxsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric AssociationBy Nasdaq OMXMay 3, 2018, 11:02 AM UTC
BusinessAxsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease AgitationBy Nasdaq OMXMay 8, 2017, 11:01 AM UTC
BusinessAxsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease AgitationBy Nasdaq OMXJan 3, 2017, 12:01 PM UTC
BusinessAxsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease AgitationBy Nasdaq OMXJan 3, 2017, 12:01 PM UTC
BusinessAxsome Therapeutics Receives Pre-IND Guidance from FDA for AXS-05 for Agitation in Patients with Alzheimer’s DiseaseBy Nasdaq OMXApr 20, 2016, 11:00 AM UTC
